Published in J Nucl Med on July 15, 2011
Brain β-amyloid load approaches a plateau. Neurology (2013) 2.50
The history of cerebral PET scanning: from physiology to cutting-edge technology. Neurology (2013) 2.04
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology (2012) 1.34
Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.25
Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging (2012) 1.19
Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther (2011) 1.07
Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology (2012) 1.04
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease. Neuroimage Clin (2013) 1.02
Binding of the radioligand SIL23 to α-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS One (2013) 1.00
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol (2012) 0.94
Imaging biomarkers associated with cognitive decline: a review. Biol Psychiatry (2014) 0.94
Amyloid-β positron emission tomography imaging probes: a critical review. J Alzheimers Dis (2013) 0.90
Beta-amyloid imaging with florbetaben. Clin Transl Imaging (2015) 0.89
Amyloid PET imaging: applications beyond Alzheimer's disease. Clin Transl Imaging (2015) 0.88
Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov Disord (2015) 0.87
Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging (2015) 0.86
A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. Biomed Res Int (2014) 0.85
(18)F-florbetaben Aβ imaging in mild cognitive impairment. Alzheimers Res Ther (2013) 0.84
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 0.83
Multimodality imaging of Alzheimer disease and other neurodegenerative dementias. J Nucl Med (2014) 0.82
Advances in high-field magnetic resonance spectroscopy in Alzheimer's disease. Curr Alzheimer Res (2014) 0.82
Glyconanoparticle aided detection of β-amyloid by magnetic resonance imaging and attenuation of β-amyloid induced cytotoxicity. ACS Chem Neurosci (2013) 0.82
Development of novel 123I-labeled pyridyl benzofuran derivatives for SPECT imaging of β-amyloid plaques in Alzheimer's disease. PLoS One (2013) 0.82
Positron emission tomography radioligands for in vivo imaging of Aβ plaques. J Labelled Comp Radiopharm (2013) 0.82
A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer's disease. Alzheimers Dement (Amst) (2015) 0.81
MR-less surface-based amyloid assessment based on 11C PiB PET. PLoS One (2014) 0.81
Recent imaging advances in neurology. J Neurol (2015) 0.81
The prognostic value of amyloid imaging. Eur J Nucl Med Mol Imaging (2012) 0.80
Amyloid-β imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies? Eur J Nucl Med Mol Imaging (2012) 0.79
Amyloid Imaging: Poised for Integration into Medical Practice. Neurotherapeutics (2017) 0.79
Biomarkers for the Early Detection and Progression of Alzheimer's Disease. Neurotherapeutics (2016) 0.78
Molecular imaging of Alzheimer disease pathology. AJNR Am J Neuroradiol (2014) 0.78
Dementia specialists and early adoption of amyloid imaging. J Alzheimers Dis (2013) 0.78
Classification of amyloid status using machine learning with histograms of oriented 3D gradients. Neuroimage Clin (2016) 0.78
Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps. Int J Alzheimers Dis (2012) 0.77
Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography. J Alzheimers Dis Parkinsonism (2014) 0.77
An update on brain imaging in parkinsonian dementia. Imaging Med (2012) 0.77
Imaging Amyloidopathy in Parkinson Disease and Parkinsonian Dementia Syndromes. Clin Transl Imaging (2015) 0.77
Synthesis, characterization, and preclinical validation of a PET radiopharmaceutical for interrogating Aβ (β-amyloid) plaques in Alzheimer's disease. EJNMMI Res (2015) 0.77
Amyloid-β probes: Review of structure-activity and brain-kinetics relationships. Beilstein J Org Chem (2013) 0.77
Fluselenamyl: A Novel Benzoselenazole Derivative for PET Detection of Amyloid Plaques (Aβ) in Alzheimer's Disease. Sci Rep (2016) 0.77
Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain (2016) 0.77
Florbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain. Neurol Ther (2014) 0.77
FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice. EJNMMI Res (2015) 0.77
Brain Amyloid Deposition and Longitudinal Cognitive Decline in Nondemented Older Subjects: Results from a Multi-Ethnic Population. PLoS One (2015) 0.76
Recent advances in neuroimaging biomarkers in geriatric psychiatry. Curr Psychiatry Rep (2013) 0.76
Identification of promethazine as an amyloid-binding molecule using a fluorescence high-throughput assay and MALDI imaging mass spectrometry. Neuroimage Clin (2013) 0.76
Alzheimer's disease diagnostic criteria: practical applications. Alzheimers Res Ther (2012) 0.76
Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis. Eur J Nucl Med Mol Imaging (2015) 0.76
A review of neuroimaging biomarkers of Alzheimer's disease. Neurol Asia (2013) 0.75
Retinal vascular and structural changes are associated with amyloid burden in the elderly: ophthalmic biomarkers of preclinical Alzheimer's disease. Alzheimers Res Ther (2017) 0.75
Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT. Front Pharmacol (2016) 0.75
Insight into the Molecular Imaging of Alzheimer's Disease. Int J Biomed Imaging (2016) 0.75
Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. Transl Neurodegener (2017) 0.75
Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients. Medicine (Baltimore) (2017) 0.75
Evaluation of [(11) C]TAZA for amyloid β plaque imaging in postmortem human Alzheimer's disease brain region and whole body distribution in rodent PET/CT. Synapse (2016) 0.75
Amyloid imaging in depression: a predictor of Alzheimer's disease? Eur J Nucl Med Mol Imaging (2014) 0.75
(18)F-Florbetaben PET beta-amyloid binding expressed in Centiloids. Eur J Nucl Med Mol Imaging (2017) 0.75
Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am (2007) 24.18
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Prevalence of primary and revision total hip and knee arthroplasty in the United States from 1990 through 2002. J Bone Joint Surg Am (2005) 7.56
The Accelerated Child Survival and Development programme in west Africa: a retrospective evaluation. Lancet (2010) 6.56
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov (2004) 5.82
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging (2010) 5.49
The epidemiology of revision total hip arthroplasty in the United States. J Bone Joint Surg Am (2009) 5.33
Future young patient demand for primary and revision joint replacement: national projections from 2010 to 2030. Clin Orthop Relat Res (2009) 4.49
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2005) 4.34
The epidemiology of revision total knee arthroplasty in the United States. Clin Orthop Relat Res (2009) 3.94
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 3.67
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol (2003) 3.58
Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol (2010) 3.46
Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol (2002) 3.30
PI(3)Kgamma has an important context-dependent role in neutrophil chemokinesis. Nat Cell Biol (2006) 3.12
WHO and UNICEF estimates of national infant immunization coverage: methods and processes. Bull World Health Organ (2009) 3.10
Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol (2012) 3.03
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
Street lighting disturbs commuting bats. Curr Biol (2009) 2.95
Levels and trends in under-5 mortality, 1990-2008. Lancet (2009) 2.86
A primer of amyloid nomenclature. Amyloid (2007) 2.70
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet (2011) 2.50
Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell (2010) 2.46
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron (2008) 2.30
The epidemiology of bearing surface usage in total hip arthroplasty in the United States. J Bone Joint Surg Am (2009) 2.28
Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid (2005) 2.14
Derivatives of 1,5-diamino-1H-tetrazole: a new family of energetic heterocyclic-based salts. Inorg Chem (2005) 2.07
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem (2002) 1.99
Homo- and heterodimerization of APP family members promotes intercellular adhesion. EMBO J (2005) 1.98
C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum Mol Genet (2006) 1.97
A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry (2002) 1.93
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med (2013) 1.93
Levels and trends in child mortality, 1990-2009. Lancet (2010) 1.92
Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β-amyloid imaging. Brain (2011) 1.92
Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet (2003) 1.91
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement (2013) 1.87
IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation. Am J Physiol Lung Cell Mol Physiol (2003) 1.86
Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J Neurosci (2008) 1.86
Taxon-specific PCR for DNA barcoding arthropod prey in bat faeces. Mol Ecol Resour (2010) 1.84
Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci (2005) 1.83
In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging (2014) 1.80
Mortality following the diagnosis of a vertebral compression fracture in the Medicare population. J Bone Joint Surg Am (2008) 1.80
Fellatio by fruit bats prolongs copulation time. PLoS One (2009) 1.77
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Patient-related risk factors for periprosthetic joint infection and postoperative mortality following total hip arthroplasty in Medicare patients. J Bone Joint Surg Am (2012) 1.76
Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem (2002) 1.74
18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain (2011) 1.67
PrPC-related signal transduction is influenced by copper, membrane integrity and the alpha cleavage site. Cell Res (2009) 1.64
The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation. J Biol Chem (2004) 1.63
Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry (2006) 1.63
Dopamine D2 receptor knockout mice develop features of Parkinson disease. Ann Neurol (2009) 1.62
Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia (2011) 1.62
An aerial-hawking bat uses stealth echolocation to counter moth hearing. Curr Biol (2010) 1.60
Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med (2007) 1.60
Amyloid fibril protein nomenclature -- 2002. Amyloid (2002) 1.59
Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain (2012) 1.58
Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med (2013) 1.58
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.58
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis (2010) 1.57
Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One (2007) 1.55
Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease. BMC Bioinformatics (2014) 1.53
Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. FASEB J (2008) 1.52
In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci (2007) 1.52
Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J (2005) 1.51